trending Market Intelligence /marketintelligence/en/news-insights/trending/nyaVLHSKz8WFUE9cx-dA7A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Coherus, Daiichi Sankyo end Enbrel biosimilar license deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Coherus, Daiichi Sankyo end Enbrel biosimilar license deal

Coherus Biosciences Inc. and Daiichi Sankyo Co. Ltd. terminated their contract regarding Coherus' Enbrel biosimilar product candidate CHS-0214.

The contract termination is due to Daiichi Sankyo's recent decision to discontinue development of CHS-0214 in Japan.

Coherus will not incur any early termination penalties.

Amgen Inc.'s Enbrel, or etanercept, is used to treat patients with moderately to severely active rheumatoid arthritis.